Merit Medical Systems (MMSI) released 12-month efficacy results for its WRAPSODY Cell-Impermeable Endoprosthesis (“CIE”), demonstrating strong performance in vascular access maintenance. Designed to enhance long-term outcomes for patients with end-stage renal disease, WRAPSODY CIE leverages advanced technology to improve vessel patency and reduce complications.This milestone underscores Merit Medical's dedication to innovation in interventional medicine. With promising clinical data, WRAPSODY CIE reinforces ...

At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively.At 12 months, the WRAPSODY CIE achieved 70.1% and 58.1% target lesion primary patency and access circuit primary patency, respectively. SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Acc ...

SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred Lampropoulos, will visit the Nasdaq MarketSite in Times Square to ring the opening bell on Wednesday, March 19, 2025. The ceremony begins at 9:15 A.M. (EDT) and the bell ringing takes place at 9:30 A.M. "Merit’s listing on Nasdaq for 35 years marks a significant milestone in our company’s history,” said Lampropo ...

Group 1 - Medical technology companies have experienced a "flight to safety" in 2025, benefiting from increased investor interest [1] - Merit Medical (NASDAQ: MMSI) has outperformed the market, with shares rising nearly 20% since the last analysis [1]

Merit Medical Systems, Inc. (MMSI) , on Monday, announced the enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in premature infants (PREEMIE study). The PREEMIE study is an Investigational Device Exemption study.It should be noted that the Bloom Micro Occluder System is not currently approved to treat PDA.MMSI plans to enroll at least 55 premature infants with hemodynamically significant or large PDA ...

SOUTH JORDAN, Utah, March 10, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in premature infants (PREEMIE study). PDA is a congenital heart condition that occurs when the ductus arteriosus, a blood vessel connecting the aorta and pulmonary artery, does not close following bi ...

Core Insights - Merit Medical Systems, Inc. has initiated a multicenter, prospective study named PREEMIE to evaluate the safety and efficacy of the Bloom Micro Occluder System for treating patent ductus arteriosus (PDA) in premature infants [1][4] - The Bloom Micro Occluder System is designed as a minimally invasive treatment option for hemodynamically significant PDAs, utilizing a flexible delivery system to insert a self-expanding nitinol device [3][4] - The study aims to enroll at least 55 premature infants weighing between 600 g and 2,500 g across up to ten U.S. study sites, with a focus on assessing safety and efficacy over a six-month period [3][4] Company Overview - Merit Medical Systems, Inc. was founded in 1987 and specializes in the development, manufacture, and distribution of proprietary medical devices for interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy [5] - The company has a global presence with a sales force and clinical support team of over 800 individuals and employs approximately 7,400 people worldwide [5] Industry Context - Patent ductus arteriosus (PDA) is a common congenital heart condition in premature, low-birth-weight infants, which can negatively impact health and often requires treatment [2] - Current treatment options for PDA in small premature infants are limited, making the Bloom Micro Occluder System a potentially significant advancement in pediatric interventional cardiology [4]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was reported at $355.2 million, representing a 9% year-over-year increase on a GAAP basis and a 10% increase on a constant currency basis [11][12] - Non-GAAP operating profit grew by 30%, with a non-GAAP operating margin of 19.6%, up approximately 305 basis points year-over-year [13][29] - Non-GAAP earnings per share increased by 26%, exceeding expectations [13][30] - Free cash flow generation for the fiscal year 2024 was over $185 million, up 67% year-over-year [14][30] Business Line Data and Key Metrics Changes - Cardiovascular segment sales grew by 8%, while the Endoscopy segment saw an impressive 88% growth [18] - Peripheral Intervention (PI) products increased by 5.5%, driven by strong sales in axis and embolotherapy products [20] - Cardiac Intervention product sales rose by 7%, with organic growth of approximately 1% [22] - OEM product sales surged by 22%, indicating strong demand in the U.S. despite challenges in international markets [23] Market Data and Key Metrics Changes - U.S. sales increased nearly 14% on a constant currency basis, exceeding expectations [24] - International sales grew by 5% year-over-year, with a 2% increase on an organic constant currency basis [24] - Sales in the APAC region showed modest growth of 4%, while EMEA sales were softer due to challenges in Russia and distributor markets [25] Company Strategy and Development Direction - The company aims for continued strong execution, solid constant currency growth, and improving profitability in 2025, alongside progress in its CGI program [15] - Financial guidance for 2025 includes net revenue growth of 8% to 10% year-over-year, with specific growth targets for cardiovascular and endoscopy segments [34] - The company is focused on maintaining a minimum of 5% organic constant currency growth and achieving operating margins of at least 20% [57] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's momentum and the ability to meet financial guidance for 2025 [15] - The impact of tariffs and potential retaliatory measures remains uncertain, with management monitoring the situation closely [38][39] - The company is optimistic about the WRAPSODY program and its market response, with upcoming presentations expected to provide further insights [45][72] Other Important Information - The company generated $65 million of free cash flow in Q4 2024, contributing to a total of over $185 million for the fiscal year [30][31] - As of December 31, 2024, the company had cash and cash equivalents of $376.7 million and total debt obligations of $747.5 million [32] Q&A Session Summary Question: EPS guidance concerns - Management acknowledged the conservative EPS guidance due to increased interest expenses and accounting treatment of convertible debt, impacting growth expectations [48][52] Question: OEM growth expectations - Management indicated strong demand in the U.S. for OEM products, with confidence in maintaining growth levels [64][67] Question: WRAPSODY revenue guidance - WRAPSODY's revenue guidance of $7 million to $9 million was confirmed to be included in overall financial guidance [87] Question: Endoscopy segment guidance - Management provided insights on the integration of sales forces and expressed confidence in achieving the guidance set for the Endoscopy segment [90][91] Question: Currency impact on revenue - Management discussed the hedging strategies in place to minimize currency impact, with a projected headwind of approximately 20 basis points [93][94] Question: Supply chain challenges - Management reported improved confidence in resolving previous supply chain issues, with ongoing monitoring [116] Question: R&D expenses - The increase in R&D expenses was attributed to short-term investments related to WRAPSODY, with expectations to return to historical levels [124][125]

Merit Medical (MMSI) reported $355.16 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 9.4%. EPS of $0.93 for the same period compares to $0.81 a year ago.The reported revenue represents a surprise of +0.93% over the Zacks Consensus Estimate of $351.87 million. With the consensus EPS estimate being $0.83, the EPS surprise was +12.05%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wal ...

Merit Medical (MMSI) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.05%. A quarter ago, it was expected that this maker of disposable medical devices would post earnings of $0.80 per share when it actually produced earnings of $0.86, delivering a surprise of 7.50%.Over the last fo ...